BioCentury | Jan 16, 2006
Finance

Ebb & Flow

...only $16.3 million in two financings. Consequently, Drug Royalty was acquired by private equity firm Inwest...
BioCentury | Dec 6, 2004
Strategy

Transforming CAT

...own pipeline. But shortly after Chambre joined CAT, Drug Royalty took a cash deal from Inwest Investments Ltd....
BioCentury | May 6, 2002
Company News

Cambridge Antibody, Drug Royalty, Inwest Investments Ltd. deal

...Holding company Inwest acquired DRI for C$3.05 in cash for each DRI share, valuing the deal...
...of accepting CAT's bid and instead recommended accepting the Inwest offer. As a result of Inwest's...
...Antibody Technology Group plc (LSE:CAT; CATG), Melbourn, U.K. Drug Royalty Corp. Inc. (TSE:DRI), Toronto, Ontario Inwest Investments Ltd....
BioCentury | Apr 1, 2002
Finance

Ebb & Flow

...its offer to acquire Drug Royalty (TSE:DRI) for C$127 million (US$79.7 million) in CAT stock. Inwest...
...of C$133 million (US$83.5 million) (see BioCentury, March 11). DRI's board has recommended taking the Inwest...
BioCentury | Apr 1, 2002
Company News

Cambridge Antibody, Drug Royalty, Inwest Investments Ltd. deal

...its recommendation of accepting CAT's bid and instead recommended an offer under which holding company Inwest...
...Antibody Technology Group plc (LSE:CAT; CATG), Melbourn, U.K. Drug Royalty Corp. Inc. (TSE:DRI), Toronto, Ontario Inwest Investments Ltd....
BioCentury | Mar 18, 2002
Finance

Ebb & Flow

...to March 27. The offer remains unchanged at C$127 million ($79.7 million) payable in stock. Inwest...
BioCentury | Mar 18, 2002
Company News

Cambridge Antibody, Drug Royalty, Inwest Investments Ltd. deal

...DRI said its board recommended an offer under which holding company Inwest will acquire DRI for...
...million (US$79.7 million) in stock (C$3 per DRI share). On March 5, DRI said that Inwest's...
...Antibody Technology Group plc (LSE:CAT; CATG) Melbourn, U.K. Drug Royalty Corp. Inc. (TSE:DRI), Toronto, Ontario Inwest Investments Ltd....
BioCentury | Mar 11, 2002
Company News

DRI's board opts for Inwest over CAT

...Drug Royalty (TSE:DRI) said its board recommended an offer under which holding company Inwest will acquire...
...million (US$79.7 million) in stock (C$3 per DRI share). On March 5, DRI said that Inwest's...
BioCentury | Mar 11, 2002
Finance

Ebb & Flow

...after Inwest Investments, a Vancouver holding company, topped CAT's offer to buy Drug Royalty (TSE:DRI). Inwest...
BioCentury | Mar 11, 2002
Company News

Cambridge Antibody, Drug Royalty, Inwest Investments Ltd. deal

...stock (C$3 per DRI share) (see BioCentury, Jan. 22). On March 5, DRI said that Inwest's...
...Antibody Technology Group plc (LSE:CAT; CATG), Melbourn, U.K. Drug Royalty Corp. Inc. (TSE:DRI), Toronto, Ontario Inwest Investments Ltd....
Items per page:
1 - 10 of 10
BioCentury | Jan 16, 2006
Finance

Ebb & Flow

...only $16.3 million in two financings. Consequently, Drug Royalty was acquired by private equity firm Inwest...
BioCentury | Dec 6, 2004
Strategy

Transforming CAT

...own pipeline. But shortly after Chambre joined CAT, Drug Royalty took a cash deal from Inwest Investments Ltd....
BioCentury | May 6, 2002
Company News

Cambridge Antibody, Drug Royalty, Inwest Investments Ltd. deal

...Holding company Inwest acquired DRI for C$3.05 in cash for each DRI share, valuing the deal...
...of accepting CAT's bid and instead recommended accepting the Inwest offer. As a result of Inwest's...
...Antibody Technology Group plc (LSE:CAT; CATG), Melbourn, U.K. Drug Royalty Corp. Inc. (TSE:DRI), Toronto, Ontario Inwest Investments Ltd....
BioCentury | Apr 1, 2002
Finance

Ebb & Flow

...its offer to acquire Drug Royalty (TSE:DRI) for C$127 million (US$79.7 million) in CAT stock. Inwest...
...of C$133 million (US$83.5 million) (see BioCentury, March 11). DRI's board has recommended taking the Inwest...
BioCentury | Apr 1, 2002
Company News

Cambridge Antibody, Drug Royalty, Inwest Investments Ltd. deal

...its recommendation of accepting CAT's bid and instead recommended an offer under which holding company Inwest...
...Antibody Technology Group plc (LSE:CAT; CATG), Melbourn, U.K. Drug Royalty Corp. Inc. (TSE:DRI), Toronto, Ontario Inwest Investments Ltd....
BioCentury | Mar 18, 2002
Finance

Ebb & Flow

...to March 27. The offer remains unchanged at C$127 million ($79.7 million) payable in stock. Inwest...
BioCentury | Mar 18, 2002
Company News

Cambridge Antibody, Drug Royalty, Inwest Investments Ltd. deal

...DRI said its board recommended an offer under which holding company Inwest will acquire DRI for...
...million (US$79.7 million) in stock (C$3 per DRI share). On March 5, DRI said that Inwest's...
...Antibody Technology Group plc (LSE:CAT; CATG) Melbourn, U.K. Drug Royalty Corp. Inc. (TSE:DRI), Toronto, Ontario Inwest Investments Ltd....
BioCentury | Mar 11, 2002
Company News

DRI's board opts for Inwest over CAT

...Drug Royalty (TSE:DRI) said its board recommended an offer under which holding company Inwest will acquire...
...million (US$79.7 million) in stock (C$3 per DRI share). On March 5, DRI said that Inwest's...
BioCentury | Mar 11, 2002
Finance

Ebb & Flow

...after Inwest Investments, a Vancouver holding company, topped CAT's offer to buy Drug Royalty (TSE:DRI). Inwest...
BioCentury | Mar 11, 2002
Company News

Cambridge Antibody, Drug Royalty, Inwest Investments Ltd. deal

...stock (C$3 per DRI share) (see BioCentury, Jan. 22). On March 5, DRI said that Inwest's...
...Antibody Technology Group plc (LSE:CAT; CATG), Melbourn, U.K. Drug Royalty Corp. Inc. (TSE:DRI), Toronto, Ontario Inwest Investments Ltd....
Items per page:
1 - 10 of 10